These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

161 related items for PubMed ID: 9433512

  • 1. Left ventricular anatomy and function in primary aldosteronism and renovascular hypertension.
    Pessina AC, Sacchetto A, Rossi GP.
    Adv Exp Med Biol; 1997; 432():63-9. PubMed ID: 9433512
    [Abstract] [Full Text] [Related]

  • 2. Role of aldosterone in left ventricular hypertrophy in hypertension.
    Matsumura K, Fujii K, Oniki H, Oka M, Iida M.
    Am J Hypertens; 2006 Jan; 19(1):13-8. PubMed ID: 16461184
    [Abstract] [Full Text] [Related]

  • 3. Cardiac consequences of aldosterone excess in human hypertension.
    Rossi GP.
    Am J Hypertens; 2006 Jan; 19(1):10-2. PubMed ID: 16461183
    [No Abstract] [Full Text] [Related]

  • 4. [Left ventricular myocardial structure and function in patients with primary aldosteronism].
    Arabidze GG, Chikhladze NM, Sergakova LM, Iarovaia EB.
    Ter Arkh; 1999 Jan; 71(9):13-9. PubMed ID: 10553618
    [Abstract] [Full Text] [Related]

  • 5. Comparison of changes in cardiac structure after treatment in secondary hypertension.
    Yoshitomi Y, Nishikimi T, Abe H, Yoshiwara F, Suzuki T, Ashizawa A, Nagata S, Kuramochi M, Matsuoka H, Omae T.
    Hypertension; 1996 Mar; 27(3 Pt 1):319-23. PubMed ID: 8698432
    [Abstract] [Full Text] [Related]

  • 6. Long-term cardiac effects of adrenalectomy or mineralocorticoid antagonists in patients with primary aldosteronism.
    Catena C, Colussi G, Lapenna R, Nadalini E, Chiuch A, Gianfagna P, Sechi LA.
    Hypertension; 2007 Nov; 50(5):911-8. PubMed ID: 17893375
    [Abstract] [Full Text] [Related]

  • 7. Long-term control of arterial hypertension and regression of left ventricular hypertrophy with treatment of primary aldosteronism.
    Rossi GP, Cesari M, Cuspidi C, Maiolino G, Cicala MV, Bisogni V, Mantero F, Pessina AC.
    Hypertension; 2013 Jul; 62(1):62-9. PubMed ID: 23648698
    [Abstract] [Full Text] [Related]

  • 8. Left ventricular structural characteristics in unilateral renovascular hypertension and primary aldosteronism.
    Suzuki T, Abe H, Nagata S, Saitoh F, Iwata S, Ashizawa A, Kuramochi M, Omae T.
    Am J Cardiol; 1988 Dec 01; 62(17):1224-7. PubMed ID: 2973734
    [Abstract] [Full Text] [Related]

  • 9. Left ventricular structural and functional characteristics in patients with renovascular hypertension, primary aldosteronism and essential hypertension.
    Yoshihara F, Nishikimi T, Yoshitomi Y, Nakasone I, Abe H, Matsuoka H, Omae T.
    Am J Hypertens; 1996 Jun 01; 9(6):523-8. PubMed ID: 8783775
    [Abstract] [Full Text] [Related]

  • 10. Aldosterone induces left ventricular subclinical systolic dysfunction: a strain imaging study.
    Chen ZW, Huang KC, Lee JK, Lin LC, Chen CW, Chang YY, Liao CW, Wu VC, Hung CS, Lin YH, TAIPAI study group.
    J Hypertens; 2018 Feb 01; 36(2):353-360. PubMed ID: 28902663
    [Abstract] [Full Text] [Related]

  • 11. Changes in left ventricular anatomy and function in hypertension and primary aldosteronism.
    Rossi GP, Sacchetto A, Visentin P, Canali C, Graniero GR, Palatini P, Pessina AC.
    Hypertension; 1996 May 01; 27(5):1039-45. PubMed ID: 8621194
    [Abstract] [Full Text] [Related]

  • 12. Regression of left ventricular hypertrophy in patients with primary aldosteronism/low-renin hypertension on low-dose spironolactone.
    Ori Y, Chagnac A, Korzets A, Zingerman B, Herman-Edelstein M, Bergman M, Gafter U, Salman H.
    Nephrol Dial Transplant; 2013 Jul 01; 28(7):1787-93. PubMed ID: 23378418
    [Abstract] [Full Text] [Related]

  • 13. Left ventricular hypertrophy precedes other target-organ damage in primary aldosteronism.
    Shigematsu Y, Hamada M, Okayama H, Hara Y, Hayashi Y, Kodama K, Kohara K, Hiwada K.
    Hypertension; 1997 Mar 01; 29(3):723-7. PubMed ID: 9052887
    [Abstract] [Full Text] [Related]

  • 14. Anti-aldosterone treatment and the prevention of myocardial fibrosis in primary and secondary hyperaldosteronism.
    Brilla CG, Matsubara LS, Weber KT.
    J Mol Cell Cardiol; 1993 May 01; 25(5):563-75. PubMed ID: 8377216
    [Abstract] [Full Text] [Related]

  • 15. Reversal of myocardial fibrosis in patients with unilateral hyperaldosteronism receiving adrenalectomy.
    Lin YH, Lee HH, Liu KL, Lee JK, Shih SR, Chueh SC, Lin WC, Lin LC, Lin LY, Chung SD, Wu VC, Kuo CC, Ho YL, Chen MF, Wu KD, TAIPAI Study Group.
    Surgery; 2011 Sep 01; 150(3):526-33. PubMed ID: 21514614
    [Abstract] [Full Text] [Related]

  • 16. Predictive factors of left ventricular mass changes after treatment of primary aldosteronism.
    Catena C, Colussi GL, Marzano L, Sechi LA.
    Horm Metab Res; 2012 Mar 01; 44(3):188-93. PubMed ID: 22351477
    [Abstract] [Full Text] [Related]

  • 17. Antifibrotic effects of spironolactone in preventing myocardial fibrosis in systemic arterial hypertension.
    Brilla CG, Matsubara LS, Weber KT.
    Am J Cardiol; 1993 Jan 21; 71(3):12A-16A. PubMed ID: 8421998
    [Abstract] [Full Text] [Related]

  • 18. Adrenalectomy reverses myocardial fibrosis in patients with primary aldosteronism.
    Lin YH, Wu XM, Lee HH, Lee JK, Liu YC, Chang HW, Lin CY, Wu VC, Chueh SC, Lin LC, Lo MT, Ho YL, Wu KD, TAIPAI Study Group.
    J Hypertens; 2012 Aug 21; 30(8):1606-13. PubMed ID: 22688266
    [Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 9.